小细胞癌：综合治疗方法。
Small cell carcinoma: combined approach to treatment.
作者信息
Gregor A, Morgan P G, Morgan R L, Scadding F H, Turner-Warwick M
出版信息
Thorax. 1979 Dec;34(6):789-93. doi: 10.1136/thx.34.6.789.
Fifty-six patients with untreated small cell carcinoma of the bronchus were treated with three courses of chemotherapy (cyclophosphamide, vincristine, and procarbazine and methotrexate) and assessed for response. Thirty-one patients (55.4%) were classified as responders; they were given a course of radiotherapy and were then randomly allocated to continued cyclical chemotherapy or not further chemotherapy until relapse. Non-responders to chemotherapy were treated with radiotherapy or palliatively. The median survival was 10.5 months in responders and 6 months in non-responders (P less than 0.01). The one-year survival in responders was 42%. There was no statistical difference in survival between patients treated with continued chemotherapy and those treated at relapse. Sixty-nine per cent of patients experienced no side effects from chemotherapy. Three indicators of non-response to chemotherapy were identified--exercise tolerance at diagnosis, macroscopic liver metastases, and inappropriate ADH secretion.
56例未经治疗的支气管小细胞癌患者接受了三个疗程的化疗（环磷酰胺、长春新碱、丙卡巴肼和甲氨蝶呤），并评估疗效。31例患者（55.4%）被归类为有反应者；他们接受了一个疗程的放射治疗，然后被随机分配继续进行周期性化疗或不再进行化疗直至复发。化疗无反应者接受放射治疗或姑息治疗。有反应者的中位生存期为10.5个月，无反应者为6个月（P<0.01）。有反应者的一年生存率为42%。继续化疗的患者与复发时接受治疗的患者在生存率上无统计学差异。69%的患者未出现化疗副作用。确定了三个化疗无反应指标——诊断时的运动耐量、肉眼可见的肝转移和抗利尿激素分泌异常。
Zotero 插件